Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers msp-1, msp-2, and glurp.

Jones S, Kay K, Hodel EM, Chy S, Mbituyumuremyi A, Uwimana A, Menard D, Felger I, Hastings I.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00590-19. doi: 10.1128/AAC.00590-19. Print 2019 Sep.

2.

Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance.

Jones S, Hodel EM, Sharma R, Kay K, Hastings IM.

J Infect Dis. 2019 Apr 8;219(8):1243-1253. doi: 10.1093/infdis/jiy649.

3.

Modelling the impact of insecticide-based control interventions on the evolution of insecticide resistance and disease transmission.

Barbosa S, Kay K, Chitnis N, Hastings IM.

Parasit Vectors. 2018 Aug 28;11(1):482. doi: 10.1186/s13071-018-3025-z.

4.

Insecticide resistance evolution with mixtures and sequences: a model-based explanation.

South A, Hastings IM.

Malar J. 2018 Feb 15;17(1):80. doi: 10.1186/s12936-018-2203-y.

5.

A Two-Locus Model of the Evolution of Insecticide Resistance to Inform and Optimise Public Health Insecticide Deployment Strategies.

Levick B, South A, Hastings IM.

PLoS Comput Biol. 2017 Jan 17;13(1):e1005327. doi: 10.1371/journal.pcbi.1005327. eCollection 2017 Jan.

6.

Quantifying the pharmacology of antimalarial drug combination therapy.

Hastings IM, Hodel EM, Kay K.

Sci Rep. 2016 Sep 8;6:32762. doi: 10.1038/srep32762.

7.

The Importance of Scientific Debate in the Identification, Containment, and Control of Artemisinin Resistance.

Hastings IM, Kay K, Hodel EM.

Clin Infect Dis. 2016 Dec 1;63(11):1527-1528. Epub 2016 Aug 23. No abstract available.

PMID:
27558565
8.
9.

Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment.

Hodel EM, Kay K, Hastings IM.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2747-56. doi: 10.1128/AAC.01172-15. Print 2016 May.

10.

Reply to "Parasite Strain, Host Immunity, and Circulating Blood Cells with Dead Parasites: Why Predicting Malaria Parasite Clearance Is Not a Simple Task".

Hastings IM, Kay K, Hodel EM.

Antimicrob Agents Chemother. 2016 Jan 29;60(2):1173-4. doi: 10.1128/AAC.02570-15. Print 2016 Feb. No abstract available.

11.

Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy.

Tirados I, Esterhuizen J, Kovacic V, Mangwiro TN, Vale GA, Hastings I, Solano P, Lehane MJ, Torr SJ.

PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003822. doi: 10.1371/journal.pntd.0003822. eCollection 2015.

12.

Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.

Kay K, Hodel EM, Hastings IM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6419-27. doi: 10.1128/AAC.00482-15. Epub 2015 Aug 3.

13.

How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

Hastings IM, Kay K, Hodel EM.

Antimicrob Agents Chemother. 2015 Oct;59(10):6428-36. doi: 10.1128/AAC.00481-15. Epub 2015 Aug 3.

14.

Measuring windows of selection for anti-malarial drug treatments.

Kay K, Hastings IM.

Malar J. 2015 Jul 31;14:292. doi: 10.1186/s12936-015-0810-4.

15.

Mathematical models of human african trypanosomiasis epidemiology.

Rock KS, Stone CM, Hastings IM, Keeling MJ, Torr SJ, Chitnis N.

Adv Parasitol. 2015 Mar;87:53-133. doi: 10.1016/bs.apar.2014.12.003. Epub 2015 Feb 11. Review.

PMID:
25765194
16.

Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.

Kay K, Hodel EM, Hastings IM.

Antimicrob Agents Chemother. 2014 Oct;58(10):5643-9. doi: 10.1128/AAC.02777-14. Epub 2014 Jun 30.

17.

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.

Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM.

Malar J. 2014 Apr 7;13:138. doi: 10.1186/1475-2875-13-138.

18.

Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?

Hastings IM, Hodel EM.

Malar J. 2014 Feb 20;13:62. doi: 10.1186/1475-2875-13-62. Review.

19.
20.

The importance of mosquito behavioural adaptations to malaria control in Africa.

Gatton ML, Chitnis N, Churcher T, Donnelly MJ, Ghani AC, Godfray HC, Gould F, Hastings I, Marshall J, Ranson H, Rowland M, Shaman J, Lindsay SW.

Evolution. 2013 Apr;67(4):1218-30. doi: 10.1111/evo.12063. Epub 2013 Feb 15. Review.

21.

Analysing malaria drug trials on a per-individual or per-clone basis: a comparison of methods.

Jaki T, Parry A, Winter K, Hastings I.

Stat Med. 2013 Jul 30;32(17):3020-38. doi: 10.1002/sim.5706. Epub 2012 Dec 19.

PMID:
23258694
22.

Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach.

Antao T, Hastings I.

Malar J. 2012 Dec 17;11:422. doi: 10.1186/1475-2875-11-422.

23.

Entomological indices of malaria transmission in Chikhwawa district, Southern Malawi.

Mzilahowa T, Hastings IM, Molyneux ME, McCall PJ.

Malar J. 2012 Nov 21;11:380. doi: 10.1186/1475-2875-11-380.

24.

The geographical distribution of allele polymorphisms of Plasmodium vivax in different regions of Thailand.

Kosaisavee V, Hastings I, Craig A, Lek-Uthai U.

J Med Assoc Thai. 2012 Jun;95 Suppl 6:S135-40.

PMID:
23130499
25.
26.

The genetic polymorphism of Plasmodium vivax genes in endemic regions of Thailand.

Kosaisavee V, Hastings I, Craig A, Lek-Uthai U.

Asian Pac J Trop Med. 2011 Dec;4(12):931-6. doi: 10.1016/S1995-7645(11)60221-6.

27.

Challenges in estimating insecticide selection pressures from mosquito field data.

Barbosa S, Black WC 4th, Hastings I.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1387. doi: 10.1371/journal.pntd.0001387. Epub 2011 Nov 1.

28.

Prediction of hospital mortality from admission laboratory data and patient age: a simple model.

Asadollahi K, Hastings IM, Gill GV, Beeching NJ.

Emerg Med Australas. 2011 Jun;23(3):354-63. doi: 10.1111/j.1742-6723.2011.01410.x. Epub 2011 Apr 28.

PMID:
21668723
29.

Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Winter K, Hastings IM.

Antimicrob Agents Chemother. 2011 Jul;55(7):3380-92. doi: 10.1128/AAC.01712-10. Epub 2011 May 2.

30.

ogaraK: a population genetics simulator for malaria.

Antao T, Hastings IM.

Bioinformatics. 2011 May 1;27(9):1335-6. doi: 10.1093/bioinformatics/btr139. Epub 2011 Mar 16.

PMID:
21414984
31.

Leukocytosis as an alarming sign for mortality in patients hospitalized in general wards.

Asadollahi K, Hastings IM, Beeching NJ, Gill GV, Asadollahi P.

Iran J Med Sci. 2011 Mar;36(1):45-9.

32.

Why we should effectively treat malaria.

Hastings IM.

Trends Parasitol. 2011 Feb;27(2):51-2. doi: 10.1016/j.pt.2010.10.003. No abstract available.

PMID:
21281927
33.

Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria.

Antao T, Hastings IM.

Proc Biol Sci. 2011 Jun 7;278(1712):1705-12. doi: 10.1098/rspb.2010.1907. Epub 2010 Nov 17.

34.

How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.

Hastings I.

Trends Parasitol. 2011 Feb;27(2):67-72. doi: 10.1016/j.pt.2010.09.005.

PMID:
20971040
35.

A comparison of methods to detect and quantify the markers of antimalarial drug resistance.

Hastings IM, Nsanzabana C, Smith TA.

Am J Trop Med Hyg. 2010 Sep;83(3):489-95. doi: 10.4269/ajtmh.2010.10-0072.

36.

Field, genetic, and modeling approaches show strong positive selection acting upon an insecticide resistance mutation in Anopheles gambiae s.s.

Lynd A, Weetman D, Barbosa S, Egyir Yawson A, Mitchell S, Pinto J, Hastings I, Donnelly MJ.

Mol Biol Evol. 2010 May;27(5):1117-25. doi: 10.1093/molbev/msq002. Epub 2010 Jan 7.

37.

Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.

Marfurt J, Smith TA, Hastings IM, Müller I, Sie A, Oa O, Baisor M, Reeder JC, Beck HP, Genton B.

Malar J. 2010 Jan 7;9:8. doi: 10.1186/1475-2875-9-8.

38.

Quantifying the evolution and impact of antimalarial drug resistance: drug use, spread of resistance, and drug failure over a 12-year period in Papua New Guinea.

Nsanzabana C, Hastings IM, Marfurt J, Müller I, Baea K, Rare L, Schapira A, Felger I, Betschart B, Smith TA, Beck HP, Genton B.

J Infect Dis. 2010 Feb 1;201(3):435-43. doi: 10.1086/649784.

PMID:
20047502
39.

Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.

Babiker HA, Hastings IM, Swedberg G.

Expert Rev Anti Infect Ther. 2009 Jun;7(5):581-93. doi: 10.1586/eri.09.29. Review.

PMID:
19485798
40.

Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.

Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, Saralamba S, Day NP, White NJ, Boni MF.

Evol Appl. 2009 Feb;2(1):52-61.

41.

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.

Malar J. 2008 Nov 2;7:229. doi: 10.1186/1475-2875-7-229.

42.

MalHaploFreq: a computer programme for estimating malaria haplotype frequencies from blood samples.

Hastings IM, Smith TA.

Malar J. 2008 Jul 15;7:130. doi: 10.1186/1475-2875-7-130.

43.

Climate prediction of El Niño malaria epidemics in north-west Tanzania.

Jones AE, Wort UU, Morse AP, Hastings IM, Gagnon AS.

Malar J. 2007 Dec 6;6:162.

44.

Molecular markers as indicators of antimalarial drug failure rates.

Hastings IM.

Trop Med Int Health. 2007 Nov;12(11):1298-301. Epub 2007 Oct 22.

45.

The anatomy of a malaria disaster: drug policy choice and mortality in African children.

Hastings IM, Korenromp EL, Bloland PB.

Lancet Infect Dis. 2007 Nov;7(11):739-48. Epub 2007 Sep 19. Review.

PMID:
17884732
46.

"Sexual" population structure and genetics of the malaria agent P. falciparum.

Mzilahowa T, McCall PJ, Hastings IM.

PLoS One. 2007 Jul 18;2(7):e613.

47.

Laboratory risk factors for hospital mortality in acutely admitted patients.

Asadollahi K, Hastings IM, Beeching NJ, Gill GV.

QJM. 2007 Aug;100(8):501-7. Epub 2007 Jul 3.

PMID:
17609227
48.

Increased postpartum blood loss in pregnancies associated with placental malaria.

Uddenfeldt Wort U, Hastings I, Bergström S, Massawe S, Lipingu C, Brabin BJ.

Int J Gynaecol Obstet. 2007 Mar;96(3):171-5. Epub 2007 Feb 5.

PMID:
17280666
49.

Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance.

Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R.

Lancet Infect Dis. 2007 Feb;7(2):136-44. Review.

PMID:
17251084
50.

Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.

Hastings IM, Lalloo DG, Khoo SH.

AIDS. 2007 Jan 11;21(2):258-9; author reply 259-60. No abstract available.

PMID:
17197825

Supplemental Content

Loading ...
Support Center